MEXA  โ€ข  NASDAQ  โ€ข  BFRI US equities ยท completed weekly research
MEXA
๐Ÿ‡บ๐Ÿ‡ธ NASDAQ ยท Healthcare ยท Drug Manufacturers - Specialty & Generic

BFRI beta and relative strength

Biofrontera Inc

BFRI is strengthening above benchmark with higher sensitivity to QQQ.

Week ending Latest completed weekly edition
Next update 15:40 UK ยท after Stage Analysis
One-year beta 1.48Higher sensitivity ยท Falling
Movement explained 16%39% weekly correlation
Relative strength+39.52Strengthening above benchmark
Downside beta -2.12Upside beta 1.03
One-year excess return+28.4%53.6% stock ยท 25.2% benchmark
Directional participation

BFRI in rising and falling QQQ weeks

These percentages count what actually happened in completed weeks. They describe historical participation, not certainty about the next move.

Latest 52-week reading Directional participation is mixed

The stock sometimes follows the benchmark, but neither direction has been consistently dependable.

71% of directional weeks moved the same way.
When QQQ rose69%

BFRI also rose in 69% of 29 rising benchmark weeks.

When QQQ fell61%

BFRI also fell in 61% of 23 falling benchmark weeks.

Market state now Range-bound market with normal movement
-0.5% over 13 weeks21.8% volatility

After 41 earlier matches by market direction, more dependable when the benchmark falls.

Joined rising weeks50%
Joined falling weeks91%
Deep sample ยท 62% same-direction rate ยท 1.44 beta
Benchmark fit

BFRI sensitivity to QQQ

The benchmark relationship is partial and explains 16% of weekly movement over the latest year. Current beta is 1.48 and is falling.

Likely beta range0.52 to 2.44

A wider range means the beta estimate is less precise.

Beta stability30/100

How consistently rolling beta has held its level and direction.

Annualised alpha+32.0%

The weekly regression intercept annualised; it is historical, not expected return.

Tracking error63.8%

Annualised volatility of returns above or below the benchmark.

Relationship directionRelationship breaking down

-14.1 point change in movement explained across two distinct 26-week windows.

Beta and benchmark fitBeta is useful with context
Weaker benchmark fitStronger benchmark fitLower sensitivityHigher sensitivity

The estimate carries information, but direction, stability or the likely range should be checked before relying on it.

Historical one-week sensitivity
If QQQ rises 1%+1.03%historically associated BFRI move
If QQQ falls 1%+2.12%historically associated BFRI move
Likely beta range 0.52 to 2.44 ยท width 1.92
Can the beta be trusted?Partial relationship
Movement explained16%
Stability30%
Directional agreement71%

Rolling beta

26-week estimates show whether market sensitivity is rising or falling.

Move across the chart to inspect a completed week.
Rolling betaMarket-like beta 1.00

Rolling relationship strength

Correlation shows direction; explained movement shows how useful the relationship has been.

Move across the chart to inspect a completed week.
CorrelationMovement explained
PeriodBetaCorrelationMovement explainedAlphaExcess returnTracking error
6 months1.0133%11%+92.6%+49.8%61.9%
1 year1.4839%16%+32.0%+28.4%63.8%
2 years0.8424%6%+19.0%-24.6%69.9%
3 years0.419%1%-24.9%-182.2%92.4%
Relative strength

BFRI relative strength against QQQ

The score compares the stock/benchmark ratio with its trailing 52-week average. Above zero means the ratio is above trend; direction shows whether that advantage is building or fading.

Relative-strength trend

Current score 39.52 ยท 13-week change +62.81

Move across the chart to inspect a completed week.
Relative strengthZero baseline

Stock, benchmark and worthwhile peers

Each path starts at 100. Sector and industry appear only when their Market Structure indexes have enough constituents.

Move across the chart to inspect a completed week.
Sector ยท Healthcare+75.9 points

versus sector over 13 weeks ยท 948 constituents ยท 51% correlation

Industry ยท Drug Manufacturers - Specialty & Generic+74.7 points

versus industry over 13 weeks ยท 73 constituents ยท 53% correlation

Sensitivity to Healthcare1.68 beta

26% of weekly movement explained by the sector over one year.

Sensitivity to Drug Manufacturers - Specialty & Generic2.11 beta

28% of weekly movement explained by the industry over one year.

Return components

13-week and 52-week returns relative to QQQ

This is a return bridge, not a claim of cause. It starts with the benchmark return, then shows the difference added at sector, industry and ticker level.

Last 13 weeks+83.8 points vs benchmark
Broad market-0.5%
Sector difference+7.9%
Industry difference+1.2%
Ticker difference+74.7%

The largest source of relative strength was the ticker difference. BFRI returned 83.3%; QQQ returned -0.5%.

Last 52 weeks+28.4 points vs benchmark
Broad market+25.2%
Sector difference-15.5%
Industry difference-8.8%
Ticker difference+52.7%

The largest source of relative strength was the ticker difference. BFRI returned 53.6%; QQQ returned 25.2%.

Market conditions

BFRI in rising and falling benchmark weeks

Upside beta is higher than downside beta, a historically favourable split.

Upside beta1.03243% upside capture
Downside beta-2.12221% downside capture
Current splitMore responsive in rising markets+3.15 beta gap
ConditionWeeksBFRI averageQQQ averageBetaBeat benchmark
Benchmark up29+5.56%+2.29%1.0366%
Benchmark down23-4.06%-1.84%-2.1252%
Strongest benchmark weeks10+7.34%+4.05%1.4480%
Weakest benchmark weeks10-2.23%-3.12%-1.8960%
Quieter benchmark weeks26-0.53%+0.23%2.5854%
Historical extremes

Strongest and weakest 13-week relative periods

Distinct 13-week windows prevent one long move from filling the list with overlapping dates.

Strongest relative periods

2024-02-09 to 2024-05-03+85.3 pts

BFRI 87.0% ยท QQQ 1.6%

The return pattern shows that the industry added to the move, and the ticker moved beyond its peer backdrop.
2026-05-29 to 2026-08-21+83.8 pts

BFRI 83.3% ยท QQQ -0.5%

The return pattern shows that the sector moved the same way, and the ticker moved beyond its peer backdrop.
2024-11-22 to 2025-02-14+52.2 pts

BFRI 60.8% ยท QQQ 8.5%

The return pattern shows that the ticker moved beyond its peer backdrop.

Weakest relative periods

2023-11-17 to 2024-02-09-96.6 pts

BFRI -80.8% ยท QQQ 15.8%

The return pattern shows that the industry added to the move, and the ticker moved beyond its peer backdrop.
2022-05-27 to 2022-08-19-72.1 pts

BFRI -60.1% ยท QQQ 12.0%

The return pattern shows that the industry added to the move, and the ticker moved beyond its peer backdrop.
2021-12-31 to 2022-03-25-68.0 pts

BFRI -77.4% ยท QQQ -9.4%

The return pattern shows that the sector moved the same way, and the ticker moved beyond its peer backdrop.
Pressure and timing

Drawdowns and lead/lag relationship

The strongest link is in the same week. Lead/lag evidence is treated as secondary because timing relationships can change quickly.

Drawdown from each rolling high

Worst available drawdown: BFRI -99.8% ยท QQQ -35.1%

Move across the chart to inspect a completed week.
BFRI drawdownQQQ drawdown
Ticker leads 2w
-4%
Ticker leads 1w
-2%
Same week
9%
Benchmark leads 1w
-8%
Benchmark leads 2w
-9%
Observable signals

Signals that would confirm or change the reading

These are conditions to monitor, not price targets or forecasts.

Relative strengthAbove the zero baseline

A fall through zero would show that the stock/benchmark ratio has moved below its trailing one-year average.

Up/down beta+3.15 upside-minus-downside gap

Upside beta is higher than downside beta. The favourable split remains intact while that gap stays positive.

Exposure trendBeta is falling

Rising beta means broad-market moves are carrying more weight; falling beta means ticker-specific forces are carrying more weight.

Peer confirmation+74.7 points versus Drug Manufacturers - Specialty & Generic over 13 weeks

Strength shared by the peer group is broader; strength confined to the ticker is more company-specific and usually less stable.

Method and limits

Data and interpretation limits

Data
Completed weekly observations from 2021-11-05 to 2026-08-21 ยท 251 aligned weeks.
Current reading
52 weeks; rolling charts use 26 weeks.
Relative strength
Stock/benchmark ratio compared with its trailing 52-week average.
Peer evidence
At least 10 sector constituents and 5 industry constituents. Thin groups are excluded.
Boundary
Historical relationship analysis, not a forecast or a statement of cause. Historical relationships can break without warning.

Evidence context